Literature DB >> 26030050

Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

R Hanajiri1, M Murata1, K Sugimoto1, M Murase1, R Sakemura1, T Goto1, K Watanabe1, N Imahashi1, S Terakura1, H Ohashi2, Y Akatsuka3, S Kurahashi4, K Miyamura4, H Kiyoi1, T Nishida1, T Naoe1,5.   

Abstract

In allo-stem cell transplantation (SCT), it is unclear whether donor-specific anti-HLA Abs (DSAs) can actually mediate graft rejection or if they are simply surrogate markers for the cellular immunity that causes graft rejection. Here, we first analyzed a case of cord blood allograft rejection in which DSA and cytotoxic T lymphocyte (CTL) specific for donor HLA-B*54:01 were detected at the time of graft rejection. Both the DSA and CTL inhibited colony formation by unrelated bone marrow mononuclear cells sharing HLA-B*54:01, suggesting that the humoral and cellular immune responses were involved in the graft rejection. Interestingly, the DSA and CTL were also detected in cryopreserved pre-transplant patient blood, raising a hypothesis that the presence of anti-HLA Abs could be an indicator for corresponding HLA-specific T cells. We then evaluated the existence of HLA-specific CD8(+) T cells in other patient blood specimens having anti-HLA class I Abs. Interferon-γ enzyme-linked immunospot assays clearly confirmed the existence of corresponding HLA-specific T-cell precursors in three of seven patients with anti-HLA Abs. In conclusion, our data demonstrate that integrated humoral and cellular immunity recognizing the same alloantigen of the donor can mediate graft rejection in DSA-positive patients undergoing HLA-mismatched allo-SCT. Further studies generalizing our observation are warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26030050     DOI: 10.1038/bmt.2015.119

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  49 in total

1.  B cells versus T cells as primary barrier to hematopoietic engraftment in allosensitized recipients.

Authors:  Rainer Storb
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

2.  Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens.

Authors:  Marie Detrait; Valérie Dubois; Mohamad Sobh; Stéphane Morisset; Nathalie Tedone; Hélène Labussière; Lilia Gillis; Fiorenza Barraco; Giovanna Cannas; Sophie Ducastelle; Jihane Fatoum; Xavier Thomas; Youcef Chelgoum; Franck-Emmanuel Nicolini; Mauricette Michallet
Journal:  Exp Hematol       Date:  2012-06-12       Impact factor: 3.084

3.  Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation.

Authors:  Anna Nordlander; Michael Uhlin; Olle Ringdén; Gunilla Kumlien; Dan Hauzenberger; Jonas Mattsson
Journal:  Transpl Immunol       Date:  2011-06-21       Impact factor: 1.708

Review 4.  The role of HLA antibodies in allogeneic SCT: is the 'type-and-screen' strategy necessary not only for blood type but also for HLA?

Authors:  S Yoshihara; K Taniguchi; H Ogawa; H Saji
Journal:  Bone Marrow Transplant       Date:  2012-01-09       Impact factor: 5.483

5.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

6.  Marrow graft rejection and inhibition of growth in culture by serum in aplastic anaemia.

Authors:  A J Barrett; A Faille; F Saal; N Balitrand; E Gluckman
Journal:  J Clin Pathol       Date:  1978-12       Impact factor: 3.411

7.  Differential expression of class II MHC antigens in subpopulations of human hematopoietic progenitor cells.

Authors:  O G Ottmann; K H Nocka; M A Moore; L M Pelus
Journal:  Leukemia       Date:  1988-10       Impact factor: 11.528

8.  Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes.

Authors:  N A Kernan; N Flomenberg; B Dupont; R J O'Reilly
Journal:  Transplantation       Date:  1987-06       Impact factor: 4.939

9.  Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens.

Authors:  P J Voogt; W E Fibbe; W A Marijt; E Goulmy; W F Veenhof; M Hamilton; A Brand; F E Zwann; R Willemze; J J van Rood
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

10.  Peripheral blood stem cell allograft rejection mediated by CD4(+) T lymphocytes recognizing a single mismatch at HLA-DP beta 1*0901.

Authors:  K Fleischhauer; E Zino; B Mazzi; E Sironi; P Servida; E Zappone; E Benazzi; C Bordignon
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

View more
  2 in total

1.  Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.

Authors:  Makoto Murata; Yoshinobu Maeda; Masayoshi Masuko; Yasushi Onishi; Tomoyuki Endo; Seitaro Terakura; Yuichi Ishikawa; Chisako Iriyama; Yoko Ushijima; Tatsunori Goto; Nobuharu Fujii; Mitsune Tanimoto; Hironori Kobayashi; Yasuhiko Shibasaki; Noriko Fukuhara; Yoshihiro Inamoto; Ritsuro Suzuki; Yoshihisa Kodera; Tadashi Matsushita; Hitoshi Kiyoi; Tomoki Naoe; Tetsuya Nishida
Journal:  Cancer Sci       Date:  2017-06-29       Impact factor: 6.716

Review 2.  Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Stavroula Masouridi-Levrat; Federico Simonetta; Yves Chalandon
Journal:  Front Immunol       Date:  2016-09-16       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.